Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Change in Accured Expenses (2023 - 2025)

Historic Change in Accured Expenses for Mereo BioPharma (MREO) over the last 3 years, with Q3 2025 value amounting to -$673000.0.

  • Mereo BioPharma's Change in Accured Expenses rose 1502.53% to -$673000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$839000.0, marking a year-over-year increase of 6184.63%. This contributed to the annual value of -$1.2 million for FY2024, which is 6788.73% down from last year.
  • Latest data reveals that Mereo BioPharma reported Change in Accured Expenses of -$673000.0 as of Q3 2025, which was up 1502.53% from $1.9 million recorded in Q2 2025.
  • Mereo BioPharma's Change in Accured Expenses' 5-year high stood at $3.2 million during Q2 2024, with a 5-year trough of -$3.1 million in Q1 2023.
  • For the 3-year period, Mereo BioPharma's Change in Accured Expenses averaged around -$681777.8, with its median value being -$792000.0 (2024).
  • In the last 5 years, Mereo BioPharma's Change in Accured Expenses soared by 5878.58% in 2024 and then plummeted by 4052.39% in 2025.
  • Over the past 3 years, Mereo BioPharma's Change in Accured Expenses (Quarter) stood at -$1.7 million in 2023, then surged by 58.79% to -$706000.0 in 2024, then rose by 4.67% to -$673000.0 in 2025.
  • Its Change in Accured Expenses stands at -$673000.0 for Q3 2025, versus $1.9 million for Q2 2025 and -$1.4 million for Q1 2025.